ConductScience.org, home
Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention
API referenceFor AI assistants

Trial · NCT00723398

Results by group230

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 230

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Change in Absolute Breast DensityGroup 1: ControlAbsolute density at baseline65.53Standard Deviation 59.43cm squared
Change in Absolute Breast DensityGroup 2: Raloxifene 60 mgAbsolute density at baseline64.39Standard Deviation 39.95cm squared
Change in Absolute Breast DensityGroup 3: Raloxifene 30 mgAbsolute density at baseline65.08Standard Deviation 34.47cm squared
Change in Absolute Breast DensityGroup 4: Lovaza 4 gmAbsolute density at baseline56.35Standard Deviation 22.61cm squared
Change in Absolute Breast DensityGroup 5: Lovaza 4 gm and Raloxifene 30 mgAbsolute density at baseline63.81Standard Deviation 29.81cm squared
Change in Absolute Breast DensityGroup 1: ControlAbsolute density at 1 year59.29Standard Deviation 40.72cm squared
Change in Absolute Breast DensityGroup 2: Raloxifene 60 mgAbsolute density at 1 year60.48Standard Deviation 38.89cm squared
Change in Absolute Breast DensityGroup 3: Raloxifene 30 mgAbsolute density at 1 year59.53Standard Deviation 30.32cm squared
Change in Absolute Breast DensityGroup 4: Lovaza 4 gmAbsolute density at 1 year58.87Standard Deviation 22.21cm squared
Change in Absolute Breast DensityGroup 5: Lovaza 4 gm and Raloxifene 30 mgAbsolute density at 1 year60.93Standard Deviation 24.64cm squared
Change in Absolute Breast DensityGroup 1: ControlAbsolute density at 2 years54.34Standard Deviation 20.11cm squared
Change in Absolute Breast DensityGroup 2: Raloxifene 60 mgAbsolute density at 2 years60.57Standard Deviation 35.10cm squared
Change in Absolute Breast DensityGroup 3: Raloxifene 30 mgAbsolute density at 2 years58.86Standard Deviation 27.93cm squared
Change in Absolute Breast DensityGroup 4: Lovaza 4 gmAbsolute density at 2 years57.60Standard Deviation 20.77cm squared
Change in Absolute Breast DensityGroup 5: Lovaza 4 gm and Raloxifene 30 mgAbsolute density at 2 years28.53Standard Deviation 25.18cm squared
Changes in Biomarkers for Oxidative Stress:Urinary 8-(Isoprostane) F-2αGroup 1: ControlBaseline544Standard Error 105pg/mg creatinine
Changes in Biomarkers for Oxidative Stress:Urinary 8-(Isoprostane) F-2αGroup 2: Raloxifene 60 mgBaseline366Standard Error 39.7pg/mg creatinine
Changes in Biomarkers for Oxidative Stress:Urinary 8-(Isoprostane) F-2αGroup 3: Raloxifene 30 mgBaseline530Standard Error 107pg/mg creatinine
Changes in Biomarkers for Oxidative Stress:Urinary 8-(Isoprostane) F-2αGroup 4: Lovaza 4 gmBaseline440Standard Error 30.8pg/mg creatinine
Changes in Biomarkers for Oxidative Stress:Urinary 8-(Isoprostane) F-2αGroup 5: Lovaza 4 gm and Raloxifene 30 mgBaseline444Standard Error 54.6pg/mg creatinine

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00723398/results

API referenceFor AI assistants